Partner Case Studies

Partner	Product	Collaboration
Learn more about Naloxegol (NKTR-118) and NKTR-119	Naloxegol (NKTR-118) and NKTR-119	Nektar and AstraZeneca entered into an exclusive global licensing agreement for two of Nektar's proprietary programs, Naloxegol (NKTR-118) and NKTR-119.
	Naloxegol (NKTR-118), is a late-stage investigational product being evaluated for the treatment of opioid-induced constipation, and NKTR-119 is an early-stage program intended to deliver products for the treatment of pain without constipation side effects. Both were developed by Nektar, utilizing our proprietary small molecule advanced polymer conjugate technology platform. Both programs were discovered by Nektar.
	OMONTYS®	Nektar's proprietary PEGylation conjugation technology is used in OMONTYS®.
	OMONTYS® (peginesatide) is a synthetic, peptide-based erythropoiesis-stimulating agent under development by Takeda and Affymax. Nektar and Affymax entered into a partnership in 2004 under which Nektar provides Affymax with its Advanced PEGylation Technology to develop OMONTYS. Under the terms of the agreement, Nektar receives manufacturing revenue and other payments, as well as royalties on worldwide end product sales.
	Neulasta®	Nektar Proprietary PEGylation Technology™ is used in Neulasta®.
	Nektar technology is used in Amgen's Neulasta® (pegfilgrastim), which is prescribed to reduce the risk of infection (initially marked by fever) in patients with some tumors receiving strong chemotherapy that decreases the number of infection-fighting white blood cells. Under the terms of an agreement between Nektar and Amgen, Nektar receives manufacturing revenues for Neulasta.
	BAX 855, PEGylated rFVIII and other clotting proteins	Nektar's advanced polymer conjugate technology is used in two separate development collaborations with Baxter in Hemophilia.
	Nektar and Baxter have two separate collaborations to develop novel therapeutics to treat hemophilia using Nektar's advanced polymer conjugate technologies. Under the agreements, Nektar is entitled to receive royalties on the global sales of these programs, in addition to contract research and manufacturing revenues. The lead program, BAX 855 is a PEGylated recombinant FVIII molecule, which utilizes Nektar's proprietary PEGylation technology and Baxter's proprietary plasma and albumin free platform. The program is Baxter's most advanced longer-acting candidate, and is in Phase 1 clinical development. The new therapeutic has been designed to be a modified rFVIII with a significantly longer half life and optimized pharmacokinetics. Preclinical data presented by Baxter shows that modified rFVIII was found to have a statistically significant longer half-life compared to unmodified rFVIII as well as non-releasable, stable rFVIII conjugates.
	Amikacin Inhale	NKTR-061, the Amikacin Inhale drug-device combination product, is being developed in partnership with Bayer HealthCare.
	Amikacin Inhale will be adjunctive therapy to the current antibiotic therapies administered intravenously as standard of care. The targeted aerosol delivery platform in NKTR-061 delivers antimicrobial agent directly to the site of infection in the lungs. The product can be integrated with conventional mechanical ventilators or used as a hand-held 'off-vent' device for patients no longer requiring breathing assistance. Under the terms of the agreement with Bayer, Nektar is entitled to receive up to $125 million in development milestones for Amikacin Inhale, as well as a flat 30% royalty on product sales in the U.S. and royalties of up to 25% on sales outside of the U.S. Learn more about NKTR-061 >>
	LEVADEX™	Nektar has an intellectual property licensing agreement with MAP and is entitled to royalties on global sales of LEVADEX.
	Under the terms of an agreement between Nektar and MAP Pharmaceuticals, Nektar is entitled to receive royalties on the global sales of LEVADEX for all indications. MAP Pharmaceuticals is developing LEVADEX as a potential treatment for migraine. LEVADEX is an orally inhaled version of dihydroergotamine (DHE), self-administered via MAP's proprietary TempoŽ inhaler. A New Drug Application (NDA) for LEVADEX is currently being reviewed by the U.S. Food and Drug Administration (FDA) and the PDUFA date is March 26, 2012.
	Nektar sold certain pulmonary assets for $115 million to Novartis; the transaction closed December 31, 2008.
	Somavert®	Nektar Proprietary PEGylation Technology™ is used by Pfizer for which Nektar receives manufacturing revenues.
	PEGASYS®	Nektar Proprietary PEGylation Technology™ is used by Roche for which Nektar receives manufacturing revenues under a licensing agreement.
	MIRCERA®	Nektar Proprietary PEGylation Technology™ is used in MIRCERA. Under a collaboration with Roche, Nektar receives royalties on global sales of MIRCERA.
	PEG-INTRON®	Nektar Proprietary PEGylation Technology™ is used by Schering-Plough for PEG-INTRON which Nektar receives manufacturing revenues.
	Cimzia®	Nektar's proprietary conjugation technology is used in the novel antibody fragment through a collaboration with UCB.
	Nektar technology is used in the antibody fragment, Cimzia® (certolizumab pegol). Cimzia® is the first and only PEGylated Fab' fragment of a humanized anti-TNF-alpha antibody approved by the FDA for Crohn's disease. The product is approved in the U.S. and EU for rheumatoid arthritis. Phase 3 are currently underway in psoriatic arthritis and ankylosing spondylitis. Under the terms of the agreement between Nektar and UCB, Nektar will receive manufacturing revenues and royalties on global sales of Cimzia® for all indications.

* Neulasta® is a registered trademark of Amgen; LEVADEX™ is a trademark and Tempo® is a registered trademark of MAP Pharmaceuticals; Somavert® is a registered trademark of Pfizer; PEGASYS® is a registered trademark of Roche; MIRCERA® is a registered trademark of Roche; PEG-INTRON® is a registered trademark of Schering-Plough; Cimzia® is a registered trademark of UCB.